基本信息
章桂忠 男 硕导 中国科学院深圳先进技术研究院
电子邮件: gz.zhang@siat.ac.cn
通信地址: 广东省南山区学苑大道1068号
邮政编码: 518055
电子邮件: gz.zhang@siat.ac.cn
通信地址: 广东省南山区学苑大道1068号
邮政编码: 518055
研究领域
癌细胞生物学/肿瘤免疫/天然免疫调控机制
招生信息
招生专业
071010-生物化学与分子生物学
招生方向
癌细胞信号转导天然免疫调控机制
教育背景
2012-09--2015-06 山东大学医学院 免疫学博士2009-09--2012-06 山东大学医学院 免疫学硕士2005-09--2009-06 福州大学生物科学与工程学院 生物工程学士
学历
博士研究生
学位
博士
工作经历
工作简历
2020-01~现在, 中国科学院深圳先进技术研究院, 副研究员2015-07~2020-01,中国科学院深圳先进技术研究院, 助理研究员
专利
专利成果
[1] 万晓春, 刘曌, 章桂忠. 靶向AMPK的抑制剂/siRNA与蛋白酶体抑制剂组合在制备抗肿瘤药物中的应用. CN: CN110859960B, 2022-03-04.[2] 万晓春, 黄诗然, 章桂忠. AMPK抑制剂Compound C在治疗肿瘤药物中的应用. CN: CN110652515A, 2020-01-07.[3] 万晓春, 陈有海, 章桂忠, 刘曌, 刘绿艳. 融合蛋白抗体、增强型疫苗及其制备方法与应用. CN: CN109705224A, 2019-05-03.[4] 万晓春, 陈有海, 章桂忠, 刘曌, 刘绿艳. CD317抑制剂在制备治疗肝癌的药物中的应用. CN: CN109481685A, 2019-03-19.[5] 万晓春, 陈有海, 章桂忠, 刘曌, 刘绿艳. 一种用于治疗癌症的组合物及其应用. CN: CN109453385A, 2019-03-12.[6] 万晓春, 章桂忠, 李欣. HBs-α317ScFv重组蛋白、其编码序列、表达载体及应用. CN: CN109422813A, 2019-03-05.[7] 万晓春, 章桂忠, 李欣, 阮庆国, 范婷婷. 用于预防和/或治疗银屑病药物组合物、CD317胞外段蛋白的应用. CN: CN108295242A, 2018-07-20.[8] 万晓春, 章桂忠, 刘曌. 一种具有抗肿瘤作用的组合物及其应用. CN: CN105148124A, 2015-12-16.
出版信息
发表论文
[1] Cheng, Jian, Zhang, Guizhong, Deng, Tian, Liu, Zhao, Zhang, Mengqi, Zhang, Pengchao, Adeshakin, Funmilayo O, Niu, Xiangyun, Yan, Dehong, Wan, Xiaochun, Yu, Guang. CD317 maintains proteostasis and cell survival in response to proteasome inhibitors by targeting calnexin for RACK1-mediated autophagic degradation. CELL DEATH & DISEASE[J]. 2023, 14(5): http://dx.doi.org/10.1038/s41419-023-05858-1.[2] Dai, Liujiang, Zhang, Guizhong, Wan, Xiaochun. Network Pharmacology and Molecular Docking Analysis Reveal Insights into the Molecular Mechanism of Shengma-Gegen Decoction on Monkeypox. PATHOGENS[J]. 2022, 11(11): http://dx.doi.org/10.3390/pathogens11111342.[3] Cheng, Jian, Liu, Zhao, Deng, Tian, Lu, Zhen, Liu, Maoxuan, Lu, Xiaoxu, Adeshakin, Funmilayo Oladunni, Yan, Dehong, Zhang, Guizhong, Wan, Xiaochun. CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection. MOLECULAR IMMUNOLOGY[J]. 2021, 129: 94-102, http://dx.doi.org/10.1016/j.molimm.2020.11.002.[4] Adeshakin, Funmilayo O, Adeshakin, Adeleye O, Afolabi, Lukman O, Yan, Dehong, Zhang, Guizhong, Wan, Xiaochun. Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming. FRONTIERS IN ONCOLOGY[J]. 2021, 11: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039382/.[5] Deng, Tian, Tang, Chao, Zhang, Guizhong, Wan, Xiaochun. DAMPs released by pyroptotic cells as major contributors and therapeutic targets for CAR-T-related toxicities. CELL DEATH & DISEASE[J]. 2021, 12(1): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838657/.[6] 万晓春, 章桂忠, 邓湉, 陈倩. CD317在肿瘤发生发展及治疗方面的研究进展. 集成技术[J]. 2020, 9(6): 1-12, http://lib.cqvip.com/Qikan/Article/Detail?id=7103996791.[7] Liu, Zhao, Zhang, Guizhong, Huang, Shiran, Cheng, Jian, Deng, Tian, Lu, Xiaoxu, Adeshakin, Funmilayo Oladunni, Chen, Qian, Wan, Xiaochun. Induction of apoptosis in hematological cancer cells by dorsomorphin correlates with BAD upregulation. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS[J]. 2020, 522(3): 704-708, http://dx.doi.org/10.1016/j.bbrc.2019.11.157.[8] Zhang, Guizhong, Cheng, Jian, Liu, Zhao, Deng, Tian, Adeshakin, Funmilayo Oladunni, Wan, Xiaochun. CD317-mediated cell cytoskeleton regulation as a novel means of tumor immune evasion. JOURNAL OF IMMUNOLOGYnull. 2020, 204(1): http://apps.webofknowledge.com/CitedFullRecord.do?product=UA&colName=WOS&SID=5CCFccWmJJRAuMzNPjj&search_mode=CitedFullRecord&isickref=WOS:000589972403143.[9] Chen, Qian, Yan, Dehong, Zhang, Qingmei, Zhang, Guizhong, Xia, Meng, Li, Junxin, Zhan, Wugen, Shen, Enyun, Li, Zhihuan, Lin, Lilong, Chen, Youhai H, Wan, Xiaochun. Treatment of acetaminophen-induced liver failure by blocking the death checkpoint protein TRAIL. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE[J]. 2020, 1866(1): http://dx.doi.org/10.1016/j.bbadis.2019.165583.[10] Wan, Xiaochun, Zhang, Guizhong, Huang, Shiran, Liu, Zhao, Liu, Lvyan, Lu, Zhen, Tang, Chao. Antitumor effect of metformin: what about Burkett's lymphoma?. JOURNAL OF IMMUNOLOGYnull. 2019, 202(1): https://www.webofscience.com/wos/woscc/full-record/WOS:000524982502066.[11] Zhang, Guizhong, Li, Xin, Chen, Qian, Li, Junxin, Ruan, Qingguo, Chen, Youhai H, Yang, Xiaolu, Wan, Xiaochun. CD317 Activates EGFR by Regulating Its Association with Lipid Rafts. CANCER RESEARCH[J]. 2019, 79(9): 2220-2231, https://www.webofscience.com/wos/woscc/full-record/WOS:000466765900015.[12] Li, Junxin, Yang, Yang, Wang, Min, Ren, Xiaohu, Yang, Zheng, Liu, Lvyan, Zhang, Guizhong, Chen, Qian, Yang, Wei, Chen, Youhai H, Wan, Xiaochun. Rapid isolation of a potent human antibody against H7N9 influenza virus from an infected patient. ANTIVIRAL RESEARCH[J]. 2019, 170: 104564-, http://dx.doi.org/10.1016/j.antiviral.2019.104564.[13] Chen, Qian, Wang, Pu, Zhang, Qingmei, Xia, Meng, Zhang, Guizhong, Li, Junxin, Shen, Enyun, Chen, Youhai H, Wan, Xiaochun. Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure. JOURNAL OF MOLECULAR MEDICINE-JMM[J]. 2019, 97(9): 1247-1261, https://www.webofscience.com/wos/woscc/full-record/WOS:000483704600004.[14] Zhang, Guizhong, Li, Xin, Liu, Lvyan, Li, Junxin, Chen, Qian, Huang, Shiran, Li, Yutao, Wan, Xiaochun. Vaccination with a DNA vaccine encoding CD317-targeting HBs antigen elicits enhanced immunity in mice. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS[J]. 2018, 504(4): 865-870, http://dx.doi.org/10.1016/j.bbrc.2018.09.024.[15] Li, Junxin, Xie, Ni, Yuan, Jianhui, Liu, Lvyan, Zhou, Qiming, Ren, Xiaohu, Chen, Qian, Zhang, Guizhong, Ruan, Qingguo, Chen, Youhai H, Wan, Xiaochun. DcR3 combined with hematological traits serves as a valuable biomarker for the diagnosis of cancer metastasis. ONCOTARGET[J]. 2017, 8(64): 107612-107620, https://www.webofscience.com/wos/woscc/full-record/WOS:000419564600024.[16] Li, Xin, Zhang, Guizhong, Chen, Qian, Lin, Yingxue, Li, Junxin, Ruan, Qingguo, Chen, Youhai, Yu, Guang, Wan, Xiaochun. CD317 Promotes the survival of cancer cells through apoptosis-inducing factor. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH[J]. 2016, 35(1): http://dx.doi.org/10.1186/s13046-016-0391-2.
科研活动
科研项目
( 1 ) CD317负调控肝脏免疫应答促进肝细胞肝癌发生发展的作用机制研究, 负责人, 国家任务, 2018-01--2020-12( 2 ) CD317负调控NK细胞功能促进HCC发生发展的机制研究, 负责人, 地方任务, 2018-03--2020-03( 3 ) 靶向AMPK治疗肿瘤的作用机制研究, 负责人, 地方任务, 2020-04--2023-04( 4 ) 双抗原识别型 CAR 回路的设计合成与优化, 参与, 国家任务, 2020-01--2025-12( 5 ) CD317促进肿瘤免疫逃逸的新机制与干预研究, 负责人, 地方任务, 2023-01--2025-12( 6 ) 基20220217炎症性肠病发病机制与干预策略研究, 参与, 地方任务, 2022-11--2025-10
参与会议
(1)CD317调控肿瘤细胞蛋白稳态和生存的机制 中国免疫学会第十五届全国免疫学学术大会 2022-12-27(2)无 第十七届国际免疫学大会 2019-10-19(3)无 2017年全国免疫学大会 2017-10-26(4)Tumor-promoting Role of CD317 in Hepotocellular Carcinoma Development 2015年广东省免疫学年会 2015-09-12